Jon T. Holmlund
Geen lopende functies
Profiel
Jon T.
Holmlund is former Co-Chief Medical Officer at Galera Therapeutics, Inc., former Chief Medical Officer & Vice President-Development at Ascenta Therapeutics, Inc., former Medical Director of Aspire IRB LLC, former Vice President-Development at Ionis Pharmaceuticals, Inc. and former Principal at National Cancer Institute.
Dr. Holmlund received a doctorate from State University of New York at Buffalo.
Eerdere bekende functies van Jon T. Holmlund
Bedrijven | Functie | Einde |
---|---|---|
GALERA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31-12-2022 |
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Chief Tech/Sci/R&D Officer | 01-11-2007 |
IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-03-2004 |
Aspire IRB LLC
Aspire IRB LLC Miscellaneous Commercial ServicesCommercial Services Aspire IRB LLC operates as an independent review board that provides human subject protection oversight in clinical trials for life science companies. The private company is based in San Diego, CA and has subsidiaries in the United States. | Chief Tech/Sci/R&D Officer | - |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Opleiding van Jon T. Holmlund
State University of New York at Buffalo | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
GALERA THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
Aspire IRB LLC
Aspire IRB LLC Miscellaneous Commercial ServicesCommercial Services Aspire IRB LLC operates as an independent review board that provides human subject protection oversight in clinical trials for life science companies. The private company is based in San Diego, CA and has subsidiaries in the United States. | Commercial Services |